Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers
This grant funds clinical centers to test and optimize anti-obesity medication strategies for children and teens, focusing on health, development, and minimizing risks through collaborative research.
Funder: National Institutes of Health
Due Dates: October 9, 2026
Funding Amounts: Up to $1,000,000 per award; estimated total program funding is $3,000,000; approximately 3 awards expected.
Summary: Supports clinical centers to test and optimize anti-obesity medication strategies for children and adolescents, aiming to maximize benefits and minimize risks.
Description
This opportunity invites applications from clinical centers to join a consortium focused on evaluating and optimizing anti-obesity medication (AOM) treatment strategies for youth with obesity. The goal is to identify approaches that maximize health benefits and minimize risks, ensuring interventions support healthy growth, nutritional status, mental well-being, and quality of life, and are feasible in clinical practice. Research priorities include:
- Determining the optimal developmental stage for AOM initiation
- Assessing rate and amount of weight loss
- Comparing AOM class, dose, frequency, and duration
- Evaluating the role and intensity of adjunct lifestyle therapies
- Identifying predictors of response or nonresponse to treatment
The consortium will collaborate on protocol development, use common measures and data elements, share a central laboratory and standardized procedures, and jointly analyze and publish results. Both independent and multicenter trials are allowed. This NOFO uses the U01 cooperative agreement mechanism and is run in parallel with a companion opportunity (RFA-DK-27-136).
